Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;15(7):1501-1512.
doi: 10.1007/s13300-024-01587-6. Epub 2024 May 9.

Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects

Luis A Vázquez  1 , Santiago Tofé-Povedano  2 , Diego Bellido-Guerrero  3 , Marta Botella-Serrano  4 , Alfonso Soto-González  5 , Pedro Mezquita-Raya  6 , Elías Delgado  7 , Carmen Fajardo-Montañana  8 , Cristóbal Morales-Portillo  9 , Ana Causanilles  10 , Miriam Rubio-de Santos  11 , Irene Romera  12 , Esteban Jódar-Gimeno  13
Affiliations
Review

Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects

Luis A Vázquez et al. Diabetes Ther. 2024 Jul.

Abstract

Tirzepatide is a novel antidiabetic medication a single-molecule, agonist to the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. It is approved in the USA and EU for the treatment of type 2 diabetes mellitus (T2DM) and obesity. Due to the potential novelty represented by incorporating tirzepatide to clinical practice, we aim to review practical aspects of tirzepatide use in T2DM and the supporting scientific evidence. A group of ten endocrinologists involved as investigators in the phase 3 SURPASS clinical trial program followed a nominal group technique, a qualitative research methodology designed as a semi-structured group discussion to reach a consensus on the selection of a set of practical aspects. The scientific evidence for tirzepatide has been reviewed with respect to a number of patients' clinical profiles and care goals. Information of interest related to adverse events, special warnings and precautions, and other considerations for tirzepatide use has been included. Finally, information provided to the patients has been summarized. The practical aspects reported herein may be helpful in guiding physicians in the use of tirzepatide and contribute to optimizing the management of T2DM.

Keywords: Tirzepatide; Type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Luis A. Vázquez is advisory board member for Eli Lilly, has received speaker honoraria from AstraZeneca, Eli Lilly, and Novo Nordisk, has received research grants to institution from Eli Lilly, Novartis and Novo Nordisk, and is minor shareholder of Eli Lilly. Santiago Tofé-Povedano has received consulting, speaker and research honoraria from Eli Lilly, Novo Nordisk, AstraZeneca and GlaxoSmithKline. Diego Bellido-Guerrero is advisory board member for Eli Lilly, Novo Nordisk, Sanofi, Nestle HS, Persan Pharma, has received speaker honoraria from Novo Nordisk, Sanofi, Eli Lilly, Boehringer, Persan Pharma, Nutricia, AstraZeneca and is collaborator in national health research projects (FIS) and has participated in clinical trials of Eli Lilly, Sanofi, Bayer, Adventia Pharma, AstraZeneca, Novartis, Abbott. M.B.S has participated in clinical trials and has received speaker honoraria from Eli Lilly, Novo Nordisk, Abbot and AstraZeneca. Alfonso Soto-González is advisor on scientific boards for Novo Nordisk and Eli Lilly, has received speaker honoraria from MSD, Novo Nordisk, Eli Lilly and AstraZeneca, is collaborator in national health research projects (FIS) and has participated in clinical trials of Eli Lilly, Novo Nordisk, AstraZeneca, Bayer, Boehringer, Amgen, Pfizer and Novartis. Pedro Mezquita-Raya is advisor on scientific boards for Abbott, AstraZeneca, FAES and Novo Nordisk; lectures for AstraZeneca, Eli Lilly, FAES, Fresenius and Novo-Nordisk and performs research activities for Eli Lilly and Novo Nordisk. Elías Delgado has received unrestricted research support from AstraZeneca, Novo Nordisk, Sanofi, Pfizer, and Roche and has received consulting fees and/or honoraria for membership on advisory boards and speaker´s bureau from AstraZeneca, Novo Nordisk, Lilly, Sanofi, GlaxoSmithKline, Pfizer, Almirall, Novartis, Abbott Laboratories, Esteve, and Merck Sharp & Dohme. Carmen Fajardo-Montañana has received speaker honoraria from Eli Lilly and has participated in clinical trials of Eli Lilly. Cristóbal Morales-Portillo is advisor on scientific boards for Novo Nordisk, Lilly, MSD, Boehringer, Astra, Sanofi, Abbot; has received speaker honoraria from Sanofi, Novo Nordisk, AstraZeneca, Roche, Lilly, Boehringer, MSD, Ferrer, Janssen, Abbot; and has participated in clinical trials of Novo Nordisk, Sanofi, AstraZeneca, Pfizer, Lilly, Merck, Lexicon, FPS, Hanmi, Janssen Boehringer, Takeda, Roche, Theracos, LeeGanz. Miriam Rubio-de Santos and Irene Romera are employees of Eli Lilly. Ana Causanilles works for an independent scientific consultancy (Outcomes’10) that has received honoraria for conducting the study and writing the current manuscript. Esteban Jódar-Gimeno has received consulting honoraria from Amgen, AstraZeneca, Eli Lilly, FAES, GSK, Italfármaco, MSD, Mundipharma, Novo Nordisk, has participated in clinical research for Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GSK, Janssen, MSD, Novo Nordisk, Pfizer, Sanofi, and has received speaker honoraria from Amgen, Asofarma, AstraZeneca, Boehringer Ingelheim, Eli Lilly, FAES, MSD, Novartis, Novo Nordisk, Sanofi, Tecnofarma, ZP Pharmaceuticals.

References

    1. European Medicines Agency. Mounjaro: EPAR – Product information. https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar.... Accessed 26 Jan 2023
    1. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules [Internet]. 2022;27(13):4315. - PMC - PubMed
    1. Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388–396. doi: 10.1210/clinem/dgaa863. - DOI - PMC - PubMed
    1. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–155. doi: 10.1016/S0140-6736(21)01324-6. - DOI - PubMed
    1. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515. doi: 10.1056/NEJMoa2107519. - DOI - PubMed

LinkOut - more resources